Nasal High Flow Therapy 30 Day Readmission Study (N3ADS)

Fisher & Paykel Healthcare

Status: Terminated

Conditions: Chronic Obstructive Pulmonary Disease; COPD

Treatments: Device: NHF with or without Oxygen

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02552732

CIA138

Details and patient eligibility

About

The aim of this feasibility study is to provide data for a subsequent randomized controlled trial to investigate if patient outcomes will be improved after an acute COPD exacerbation using domiciliary nasal high flow therapy (NHF) compared to standard care. This feasibility study will investigate the following: process, resources, management and scientific aspects of delivering NHF as an adjunct therapy in COPD patients.

Enrollment: 29 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years of age or older
• Male and female
• Admitted to the respiratory ward(s) of either recruiting hospitals with AECOPD as the primary diagnostic reason for admission.

Exclusion criteria

• Given a new home oxygen therapy prescription during the current hospital admission
• The investigator believes the participant or their care giver will be unable to safely use the myAIRVO 2 device following discharge
• They have any other condition which, at the investigator's discretion, is believed may present a safety risk or impact the feasibility of the study or the study results

Trial design

Primary purpose: Device Feasibility

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

29 participants in 1 patient group

NHF with or without Oxygen

Experimental group

Description:

NHF with or without oxygen will be delivered to COPD patients using myAIRVO™ 2 for 30 days post hospital discharge

Treatment:

Device: NHF with or without Oxygen